Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology

…, Y Madanat, B McMahon, SR Mohan… - Journal of the National …, 2022 - jnccn.org
The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

[HTML][HTML] Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

…, M Levis, MM Patnaik, BL Scott, SR Mohan… - Bone marrow …, 2021 - nature.com
We evaluated standard-of-care (SOC) treatment with or without midostaurin to prevent relapse
following allogeneic hematopoietic stem cell transplant (alloHSCT) in patients with acute …

NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018

…, G Hobbs, B McMahon, SR Mohan… - Journal of the National …, 2017 - jnccn.org
Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the
hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential …

[HTML][HTML] Radius: a phase 2 randomized trial investigating standard of careħmidostaurin after allogeneic stem cell transplant in FLT3-ITD-mutated AML

RTT Maziarz, MM Patnaik, BL Scott, SR Mohan, A Deol… - Blood, 2018 - Elsevier
Introduction: Midostaurin, a multitargeted tyrosine kinase inhibitor (TKI), plus induction and
consolidation chemotherapy followed by single-agent midostaurin maintenance therapy …

[PDF][PDF] High-resolution mapping of RNA polymerases identifies mechanisms of sensitivity and resistance to BET inhibitors in t (8; 21) AML

…, MA Fischer, JE Bradner, SA Strickland, SR Mohan… - Cell reports, 2016 - cell.com
Bromodomain and extra-terminal domain (BET) family inhibitors offer an approach to treating
hematological malignancies. We used precision nuclear run-on transcription sequencing (…

Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology

…, G Hobbs, RB Klisovic, P Kropf, SR Mohan… - Journal of the National …, 2016 - jnccn.org
Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group
of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia …

The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia

…, R Jayani, A Kassim, SR Mohan… - American Journal of …, 2020 - Wiley Online Library
For patients with high risk myeloid disease, allogeneic hematopoietic cell transplantation (HCT)
is the only potentially curative therapy. Unfortunately, many of these patients relapse …

BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis

…, A Perkins, AM Vannucchi, SR Mohan… - Future …, 2022 - Future Medicine
Patients with myelofibrosis (MF) who discontinue ruxolitinib due to progression/resistance
have poor prognoses. JAK inhibitors control symptoms and reduce spleen volumes with …

Systemic mastocytosis, version 2.2019, NCCN clinical practice guidelines in oncology

…, G Hobbs, C Jamieson, B McMahon, SR Mohan… - Journal of the National …, 2018 - jnccn.org
Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of
abnormal mast cells and their accumulation in the skin and/or in various extracutaneous …

[HTML][HTML] SWOG S1203: a randomized phase III study of standard cytarabine plus daunorubicin (7+ 3) therapy versus idarubicin with high dose cytarabine (IA) with or …

…, RM Stone, DF Claxton, J Essell, S Luger, SR Mohan… - Blood, 2016 - Elsevier
Background: A majority of younger pts with AML receive initial therapy with a 7+3 scheme.
Escalated doses of daunorubicin (dauno) in combination with standard doses of ara-C may …